RecruitingPhase 2NCT07644559

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)

Sponsor

Verastem, Inc.

Enrollment

180 participants

Start Date

Jun 16, 2026

Study Type

INTERVENTIONAL

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)G12D Mutated KRAS

Summary

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called VS-7375 and a drug called cetuximab for people with g12d mutated kras and pancreatic ductal adenocarcinoma (pdac). The study is currently recruiting participants at 14 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVS-7375

Taken by mouth

DRUGcetuximab

Subcutaneous infusion

Locations(21)

START- Los Angeles

Los Angeles, California, United States

Valkyrie Clinical Trials

Los Angeles, California, United States

Moffitt Cancer Center

Tampa, Florida, United States

Johns Hopkins University

Baltimore, Maryland, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

START Midwest

Grand Rapids, Michigan, United States

Washington University

St Louis, Missouri, United States

START New Jersey

East Brunswick, New Jersey, United States

NYU-Manhattan

New York, New York, United States

University of North Carolina

Chapel Hill, North Carolina, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

START Dallas

Fort Worth, Texas, United States

MD Anderson Cancer Center

Houston, Texas, United States

START- San Antonio

San Antonio, Texas, United States

START- Mountain Region

West Valley City, Utah, United States

UVA Health

Charlottesville, Virginia, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

UW Health

Madison, Wisconsin, United States

ICON Kurralta Park

Kurralta Park, South Australia, Australia

ICON Cancer Centre

South Brisbane, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07644559

Related Trials

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

NCT076217184 locations

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT0756215231 locations

A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

NCT0725540424 locations

EUS-RFA PANCARDINAL-1 Trial

NCT049906091 location

Phase I Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Solid Tumors Like GBM and PDAC

NCT077336741 location